Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia  

作　　者：戴海萍 DAI Haiping(1 st Affil Hosp,Soochow Univ,Natl Clin Hematol Dis Res Center,Jiangsu Instit Hematol,Collab Hematol Innov Center,Instit Blood&Marrow Transpl,Soochow Univ,Suzhou 215006)

机构地区：[1]1 st Affil Hosp,Soochow Univ,Natl Clin Hematol Dis Res Center,Jiangsu Instit Hematol,Collab Hematol Innov Center,Instit Blood&Marrow Transpl,Soochow Univ,Suzhou 215006

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第2期120-120,共1页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To evaluate the efficacy and safety of chimeric antigen receptorT-cell(CAR-T)therapy followed byallogeneic hematopoietic stem cell transplantation(allo-HSCT)in patients with Ph-like acute lymphoblastic leukemia(Ph-ALL).Methods Patients with Ph-ALL who underwent CAR-T therapy followed by allo-HSCT from March 2018 to August 2023 at the First Affiliated Hospital of Soochow University were included,and their clinical data were retrospectively analyzed.Results Of the 21 patients,14 were male and 7 were female.The median age at the time of CAR-T therapy was 22(6-50)years.Seven patients had ABL1-like rearrangements,and14hadJAK-STAT rearrangements.Prior to CAR-T therapy,12 patients experienced hematologic relapse;7 were multiparameter flow cytometry minimal residual disease(MFC-MRD)-positive and 2 were MFC-MRD-negative.CAR-T cells were derived from patients'autologous lymphocytes.Nine patients were treated with CD19 CAR-T cells,and 12 were treated with CD19/CD22 CAR-T cells.After assessment on day 28 after CAR-T therapy,95.2%of the patients achieved complete remission,with an MRDnegative remission rate of 75%.

关 键 词：PATIENTS HEMATOPOIETIC LYMPHOBLASTIC 

分 类 号：R733.71[医药卫生—肿瘤]